Karpathiou Georgia, Chauleur Celine, Dal Col Pierre, Peoc'h Michel
Int J Gynecol Pathol. 2021 Nov 1;40(6):611-616. doi: 10.1097/PGP.0000000000000772.
FOXA1, a transcription factor essential for the binding of other transcription factors on chromatin, is associated with hormone receptor-associated cancers, such as breast and endometrial cancer. It is also considered an antagonist of epithelial-to-mesenchymal transition (EMT). In endometrial cancer, FOXA1 is considered a tumor suppressor; in carcinosarcoma, one of the most aggressive and rare subtypes of endometrial cancer, thought to be derived through an EMT mechanism, FOXA1 has not been studied. Thus, the aim of this study was to investigate the possible expression of FOXA1 in carcinosarcomas, and its correlation with clinicopathologic factors. This was a retrospective study of 31 patients diagnosed with carcinosarcomas of the uterus or the adnexa. Histologic and clinical factors were correlated with the immunohistochemical expression of FOXA1. FOXA1 was expressed by 38.7% of the carcinomatous components and 16.1% of the sarcomatous components. FOXA1-positive sarcomatous components were seen only with positive carcinomatous components (P=0.004). FOXA1 expression was not associated with age, primary tumor site, stage, metastases, overall survival, or tumor relapse. FOXA1 expression in the carcinomatous component was associated with an absence of lymphovascular invasion or the presence of heterologous components. FOXA1 expression in the sarcomatous component was associated with rhabdomyosarcoma, rather than the chondrosarcoma heterologous component. Carcinosarcomas harbor FOXA1 expression, although it is in their carcinomatous rather than sarcomatous components, suggesting a possible role of FOXA1 in the EMT of carcinosarcomas. FOXA1 shows no prognostic significance in this tumor group.
叉头框蛋白A1（FOXA1）是一种转录因子，对其他转录因子与染色质的结合至关重要，与激素受体相关癌症有关，如乳腺癌和子宫内膜癌。它也被认为是上皮-间质转化（EMT）的拮抗剂。在子宫内膜癌中，FOXA1被认为是一种肿瘤抑制因子；在癌肉瘤（子宫内膜癌最具侵袭性且罕见的亚型之一，被认为是通过EMT机制产生）中，尚未对FOXA1进行研究。因此，本研究的目的是调查FOXA1在癌肉瘤中的可能表达情况及其与临床病理因素的相关性。这是一项对31例诊断为子宫或附件癌肉瘤患者的回顾性研究。组织学和临床因素与FOXA1的免疫组化表达相关。38.7%的癌性成分和16.1%的肉瘤性成分表达FOXA1。仅在癌性成分呈阳性时才可见FOXA1阳性的肉瘤性成分（P = 0.004）。FOXA1表达与年龄、原发肿瘤部位、分期、转移、总生存期或肿瘤复发无关。癌性成分中的FOXA1表达与无淋巴管浸润或存在异源性成分相关。肉瘤性成分中的FOXA1表达与横纹肌肉瘤相关，而非软骨肉瘤异源性成分。癌肉瘤中存在FOXA1表达，尽管是在其癌性而非肉瘤性成分中，这表明FOXA1在癌肉瘤的EMT中可能发挥作用。FOXA1在该肿瘤组中无预后意义。
